Phase 2 Stomach Cancer Trial, Recruiting NCT06921928 Sponsor: AstraZeneca Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT06921928
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years old or older at the time of signing the consent form.
  • You must be generally well enough to carry out light activity and care for yourself, and your condition must not have gotten worse in the 2 weeks before the study begins.
  • Your doctor believes you have a life expectancy of at least 12 weeks.
  • Your liver, kidneys, and bone marrow must be functioning well enough to meet the study's requirements (confirm with trial site for specific levels).
  • You must be willing to use contraception as required by local guidelines during the study (confirm with trial site for specific requirements).
  • You must have been diagnosed with advanced or metastatic pancreatic cancer, stomach cancer, gastroesophageal junction cancer, or bile duct cancer, and your cancer must test positive for a specific protein called CLDN18.2.
  • You must have already received at least one course of treatment for your advanced or metastatic cancer.
  • You must have at least one area of cancer that can be measured on a scan.

Who may not be able to join:

  • People with stomach or gastroesophageal junction cancer that tests positive or unclear for a protein called HER2.
  • People with active stomach ulcers or bleeding in the digestive tract, including significant bleeding related to previous CLDN18.2 treatments.
  • People who have a significant build-up of fluid in the abdomen that needs to be drained.
  • People who have cancer that has spread to the brain or spinal cord, or other brain-related conditions (confirm with trial site for specific details).
  • People who have compression of the spinal cord or are at high risk of paralysis.
  • People with a history of non-infectious lung inflammation or scarring.
  • People with certain significant heart problems (confirm with trial site for specific details).
  • People who have had another type of cancer within the past 2 years.
  • People with an active hepatitis B or hepatitis C infection.
  • People with HIV that is not well managed.
  • People with an active tuberculosis infection.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
29 April 2025
Est. completion
31 March 2027

Where this trial is recruiting

🇨🇳 China 🇩🇪 Germany 🇯🇵 Japan 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov